Results 1 to 10 of about 4,080 (215)

Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ)

Medicina (Lithuania), 2021
Medication-related osteonecrosis of the jaw (MRONJ) has become a well-known side effect of antiresorptive, and antiangiogenic drugs commonly used in cancer management.
Riham Fliefel, Oliver Ristow, Suad Aljohani   +2 more
exaly   +4 more sources

Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches

Antioxidants, 2021
Medication-related osteonecrosis of the jaw (MRONJ) is one of the most interesting diseases in the field of maxillofacial surgery. In addition to bisphosphonates, the use of antiresorptive and antiangiogenic agents is known to be the leading cause ...
Sung Woon On, Seoung-Won Cho, Byoung-Eun Yang   +2 more
exaly   +3 more sources

MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors [PDF]

Bone Reports
Background: Concomitant use of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) and bone resorption inhibitors (BRIs) may increase the risk of medication-related osteonecrosis of the jaw (MRONJ).
G. Mammone, R. Coropciuc, T. Van den Wyngaert, R. Jacobs, P. Bossier, C. Kerkhofs, L. Wijnen, S. Meerschaert, E. Vissenaekens, P.M. Clement, O. Bechter, P.R. Debruyne, A. Laenen, B. Beuselinck   +13 more
doaj   +2 more sources

Bone scan index rise prior to osteonecrosis of the jaw with bone‐modifying agents in prostate cancer [PDF]

BJUI Compass
Objective This study aimed to evaluate the maximum bone scan index in the jaw (BSIJmax) before the development of clinical medication‐related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer.
Masaru Tani, Koji Hatano, Takashi Kamiya, Masatoshi Konishi, Atsuki Matsukawa, Hiromu Horitani, Syunsuke Inoguchi, Tomohiro Kanaki, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Toshiki Oka, Yohei Okuda, Gaku Yamamichi, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Tadashi Watabe, Atsunari Kawashima, Kayako Isohashi, Norio Nonomura   +22 more
doaj   +2 more sources

The Role of Cone Beam Computed Tomography (CBCT) in the Diagnosis and Clinical Management of Medication-Related Osteonecrosis of the Jaw (MRONJ)

Diagnostics
Medication-related osteonecrosis of the jaw (MRONJ) is a debilitating condition associated with antiresorptive and antiangiogenic medications that are frequently used in treating osteoporosis and cancers.
Wei-Fa Yang, Yiu Yan Leung
exaly   +3 more sources

A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients

Scientific Reports, 2022
Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a standardized protocol for the prevention of denosumab induced medication-related osteonecrosis of the jaw (MRONJ) has not yet been established. The purpose of this
Seoyeon Jung, Jaeyeon Kim, Jin Hoo Park, Ki-Yeol Kim, Hyung Jun Kim, Wonse Park   +5 more
doaj   +1 more source

Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ)

International Journal of Oral Science, 2022
Medication-related osteonecrosis of the jaw (MRONJ) is primarily associated with administering antiresorptive or antiangiogenic drugs. Despite significant research on MRONJ, its pathogenesis and effective treatments are still not fully understood. Animal
Ran Yan, Ruixue Jiang, Longwei Hu, Yuwei Deng, Jin Wen, Xinquan Jiang   +5 more
doaj   +1 more source

Novel Cell Therapy Using Mesenchymal Stromal Cell Sheets for Medication-Related Osteonecrosis of the Jaw

Frontiers in Bioengineering and Biotechnology, 2022
Despite medication-related osteonecrosis of the jaw (MRONJ) being first reported in 2003, the optimal treatment and prevention modalities for MRONJ are not clear.
Nobuyuki Kaibuchi, Nobuyuki Kaibuchi, Takanori Iwata, Takanori Iwata, Yoko Kawase Koga, Toshihiro Okamoto   +5 more
doaj   +1 more source

Medication-related osteonecrosis of the jaw treatment modalities: A review

Journal of Craniomaxillofacial Research, 2020
Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents. Management of MRONJ has remained a controversial topic within the oral and maxillofacial surgery community ...
Amir Ali Asadi
doaj   +1 more source

Medication-related osteonecrosis of the jaw: A review about etiology, risk factors, pathophysiology, and treatment

Journal of Indian Academy of Oral Medicine and Radiology, 2020
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse effect of antiresorptive and antiangiogenic medication. MRONJ is considered when a patient has exposed bone in the jaw for more than 8 weeks and has a history of antiresorptive and ...
Sheetal Singar, Ajay Pratap Singh Parihar, Prashanthi Reddy, Abhishek Maurya, Vishal Bamaniya   +4 more
doaj   +1 more source